MARKET

APLIF

APLIF

Appili Ther
OTCPK
0.0041
-0.0025
-37.88%
Closed 15:15 10/05 EDT
OPEN
0.0041
PREV CLOSE
0.0066
HIGH
0.0041
LOW
0.0041
VOLUME
100.00K
TURNOVER
410
52 WEEK HIGH
0.031
52 WEEK LOW
0.0041
MARKET CAP
542.70K
P/E (TTM)
-0.1530
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APLIF last week (0928-1002)?
Weekly Report · 10h ago
Appili Therapeutics to Delist from TSX and Move Listing to NEX
TipRanks · 6d ago
Appili Therapeutics Announces Transfer to NEX
Newsfile · 6d ago
Weekly Report: what happened at APLIF last week (0921-0925)?
Weekly Report · 09/28 09:54
Weekly Report: what happened at APLIF last week (0914-0918)?
Weekly Report · 09/21 09:54
Weekly Report: what happened at APLIF last week (0907-0911)?
Weekly Report · 09/14 09:58
Weekly Report: what happened at APLIF last week (0831-0904)?
Weekly Report · 09/07 09:53
Weekly Report: what happened at APLIF last week (0824-0828)?
Weekly Report · 08/31 09:58
More
About APLIF
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.

Webull offers Appili Therapeutics Inc stock information, including OTCPK: APLIF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLIF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLIF stock methods without spending real money on the virtual paper trading platform.